{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:34:55Z","timestamp":1788586495787,"version":"build-2803163510"},"reference-count":142,"publisher":"IMR Press","issue":"12","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Cardiomyopathies, historically regarded as rare, are increasingly recognized due to advances in imaging diagnostics and heightened clinical focus. These conditions, characterized by structural and functional abnormalities of the myocardium, pose significant challenges in both chronic and acute patient management. A thorough understanding of the hemodynamic properties, specifically the pressure-volume relationships, is essential. These relationships provide insights into cardiac function, including ventricular compliance, contractility, and overall cardiovascular performance. Despite their potential utility, pressure-volume curves are underutilized in clinical settings due to the invasive nature of traditional measurement techniques. Recognizing the dynamic nature of cardiomyopathies, with possible transitions between phenotypes, underscores the importance of continuous monitoring and adaptive therapeutic strategies. Enhanced hemodynamic evaluation can facilitate tailored treatment, potentially improving outcomes for patients with these complex cardiac conditions.<\/jats:p>","DOI":"10.31083\/j.rcm2512455","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:43:39Z","timestamp":1735555419000},"source":"Crossref","is-referenced-by-count":3,"title":["Hemodynamics in Left-Sided Cardiomyopathies"],"prefix":"10.31083","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-5352","authenticated-orcid":true,"given":"Guido","family":"Del Monaco","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-6765","authenticated-orcid":true,"given":"Francesco","family":"Amata","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-9322","authenticated-orcid":true,"given":"Vincenzo","family":"Battaglia","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-3676","authenticated-orcid":true,"given":"Cristina","family":"Panico","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-6843","authenticated-orcid":true,"given":"Gianluigi","family":"Condorelli","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve-Emanuele-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-2955","authenticated-orcid":true,"given":"Giuseppe","family":"Pinto","sequence":"first","affiliation":[{"name":"IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Humanitas Research Hospital, 20089 Rozzano-Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Arbelo E, Barriales-Villa R, et al. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). European Heart Journal. 2023; 44: 3503\u20133626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2008; 29: 270\u2013276.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Protti I, van den Enden A, Van Mieghem NM, Meuwese CL, Meani P. Looking Back, Going Forward: Understanding Cardiac Pathophysiology from Pressure-Volume Loops. Biology. 2024; 13: 55.","DOI":"10.3390\/biology13010055"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sandoval Y, Burke MN, Lobo AS, Lips DL, Seto AH, Chavez I, et al. Contemporary Arterial Access in the Cardiac Catheterization Laboratory. JACC. Cardiovascular Interventions. 2017; 10: 2233\u20132241.","DOI":"10.1016\/j.jcin.2017.08.058"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Seferovi\u0107 PM, Polovina M, Rosano G, Bozkurt B, Metra M, Heymans S, et al. State-of-the-art document on optimal contemporary management of cardiomyopathies. European Journal of Heart Failure. 2023; 25: 1899\u20131922.","DOI":"10.1002\/ejhf.2979"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Connors AF, Jr, Speroff T, Dawson NV, Thomas C, Harrell FE, Jr, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996; 276: 889\u2013897.","DOI":"10.1001\/jama.276.11.889"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Bastos MB, Burkhoff D, Maly J, Daemen J, den Uil CA, Ameloot K, et al. Invasive left ventricle pressure-volume analysis: overview and practical clinical implications. European Heart Journal. 2020; 41: 1286\u20131297.","DOI":"10.1093\/eurheartj\/ehz552"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Writing Committee Members, Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2024; 83: 2324\u20132405.","DOI":"10.1016\/j.jacc.2024.02.014"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. The New England Journal of Medicine. 2018; 379: 655\u2013668.","DOI":"10.1056\/NEJMra1710575"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: New Concepts and Therapies. Annual Review of Medicine. 2022; 73: 363\u2013375.","DOI":"10.1146\/annurev-med-042220-021539"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet (London, England). 2013; 381: 242\u2013255.","DOI":"10.1016\/S0140-6736(12)60397-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022; 79: 372\u2013389.","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC. Cardiovascular Interventions. 2011; 4: 704\u2013709.","DOI":"10.1016\/j.jcin.2011.02.014"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, Cacace A, et al. Dobutamine stress echocardiography in hypertrophic cardiomyopathy. Cardiology. 2003; 100: 93\u2013100.","DOI":"10.1159\/000073045"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gotsman MS, Lewis BS. Left ventricular volumes and compliance in hypertrophic cardiomyopathy. Chest. 1974; 66: 498\u2013505.","DOI":"10.1378\/chest.66.5.498"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Popescu BA, Rosca M, Schwammenthal E. Dynamic obstruction in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2015; 30: 468\u2013474.","DOI":"10.1097\/HCO.0000000000000199"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Murgo JP, Alter BR, Dorethy JF, Altobelli SA, McGranahan GM, Jr. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy. The Journal of Clinical Investigation. 1980; 66: 1369\u20131382.","DOI":"10.1172\/JCI109990"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Braunwald E, Brockenbrough EC, Frahm CJ, Ross J, Jr. Left atrial and left ventricular pressures in subjects without cardiovascular disease: observations in eighteen patients studied by transseptal left heart catheterization. Circulation. 1961; 24: 267\u2013269.","DOI":"10.1161\/01.CIR.24.2.267"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lasam G. Brockenbrough-Braunwald-Morrow Sign: An Evaluative Hemodynamic Maneuver for Left Ventricular Outflow Tract Obstruction. Cardiology Research. 2018; 9: 180\u2013182.","DOI":"10.14740\/cr676w"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Trevino AR, Buergler J. The Brockenbrough-Braunwald-Morrow sign. Methodist DeBakey Cardiovascular Journal. 2014; 10: 34\u201337.","DOI":"10.14797\/mdcj-10-1-34"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. Circulation Journal: Official Journal of the Japanese Circulation Society. 2013; 77: 2366\u20132374.","DOI":"10.1253\/circj.CJ-12-1561"},{"key":"ref22","unstructured":"Takahashi H, Yamaguchi R, Ifuku M, Itaya M, Koga Y, Utsu F, et al. Left ventricular function in hypertrophic cardiomyopathy: a Tc-99m radionuclide angiographic study during exercise. Journal of Cardiography. Supplement. 1986; 63\u201373."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circulation. Heart Failure. 2012; 5: 535\u2013546.","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114: 216\u2013225.","DOI":"10.1161\/CIRCULATIONAHA.105.583500"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Zhang Y, Xie W, Dai Y, Wu Z, Lin Y, Yang M, et al. Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy. ESC Heart Failure. 2024. (online ahead of print)","DOI":"10.1002\/ehf2.15010"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017; 136: 2420\u20132436.","DOI":"10.1161\/CIRCULATIONAHA.117.029267"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. Journal of the American Heart Association. 2014; 3: e001002.","DOI":"10.1161\/JAHA.114.001002"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104: 2517\u20132524.","DOI":"10.1161\/hc4601.097997"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Alphonse P, Virk S, Collins J, Campbell T, Thomas SP, Semsarian C, et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review. Clinical Research in Cardiology: Official Journal of the German Cardiac Society. 2021; 110: 544\u2013554.","DOI":"10.1007\/s00392-020-01730-w"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023; 148: 1797\u20131811.","DOI":"10.1161\/CIRCULATIONAHA.123.065037"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Zegkos T, Kamperidis V, Gossios T, Ntelios D, Parcharidou D, Papanastasiou CA, et al. Mitral regurgitation impact on left atrial myopathy in hypertrophic cardiomyopathy. Echocardiography (Mount Kisco, N.Y.). 2022; 39: 819\u2013826.","DOI":"10.1111\/echo.15370"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Debonnaire P, Joyce E, Hiemstra Y, Mertens BJ, Atsma DE, Schalij MJ, et al. Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Circulation. Arrhythmia and Electrophysiology. 2017; 10: e004052.","DOI":"10.1161\/CIRCEP.116.004052"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Guttmann OP, Pavlou M, O\u2019Mahony C, Monserrat L, Anastasakis A, Rapezzi C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2017; 103: 672\u2013678.","DOI":"10.1136\/heartjnl-2016-309672"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021; 42: 373\u2013498.","DOI":"10.1093\/eurheartj\/ehab648"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Rozen G, Elbaz-Greener G, Marai I, Andria N, Hosseini SM, Biton Y, et al. Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 2020; 9: e015721.","DOI":"10.1161\/JAHA.119.015721"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hodges K, Tang A, Rivas CG, Umana-Pizano J, Chemtob R, Desai MY, et al. Surgical ablation of atrial fibrillation in hypertrophic obstructive cardiomyopathy: Outcomes of a tailored surgical approach. Journal of Cardiac Surgery. 2020; 35: 2957\u20132964.","DOI":"10.1111\/jocs.14946"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Palandri C, Santini L, Argir\u00f2 A, Margara F, Doste R, Bueno-Orovio A, et al. Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs. 2022; 82: 889\u2013912.","DOI":"10.1007\/s40265-022-01728-w"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968; 38: 846\u2013858.","DOI":"10.1161\/01.CIR.38.5.846"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, et al. \u03b2 Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. The American Journal of Cardiology. 2012; 110: 715\u2013719.","DOI":"10.1016\/j.amjcard.2012.04.051"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Stenson RE, Flamm MD, Jr, Harrison DC, Hancock EW. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. The American Journal of Cardiology. 1973; 31: 763\u2013773.","DOI":"10.1016\/0002-9149(73)90012-X"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Thompson DS, Naqvi N, Juul SM, Swanton RH, Coltart DJ, Jenkins BS, et al. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy. British Heart Journal. 1980; 44: 488\u2013498.","DOI":"10.1136\/hrt.44.5.488"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Ladefoged BT, Andersen MJ, Jensen MK, et al. Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2022; 79: 1565\u20131575.","DOI":"10.1016\/j.jacc.2022.02.024"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Doiuchi J, Hamada M, Ochi T, Ito T, Kokubu T. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy. Clinical Cardiology. 1985; 8: 176\u2013179.","DOI":"10.1002\/clc.4960080311"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Bonow RO, Ostrow HG, Rosing DR, Cannon RO, 3rd, Lipson LC, Maron BJ, et al. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: pressure-volume analysis with a nonimaging scintillation probe. Circulation. 1983; 68: 1062\u20131073.","DOI":"10.1161\/01.CIR.68.5.1062"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. The American Journal of Cardiology. 1980; 45: 1258\u20131264.","DOI":"10.1016\/0002-9149(80)90487-7"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Anderson DM, Raff GL, Ports TA, Brundage BH, Parmley WW, Chatterjee K. Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. British Heart Journal. 1984; 51: 523\u2013529.","DOI":"10.1136\/hrt.51.5.523"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981; 64: 437\u2013441.","DOI":"10.1161\/01.CIR.64.3.437"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Betocchi S, Cannon RO, 3rd, Watson RM, Bonow RO, Ostrow HG, Epstein SE, et al. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. Circulation. 1985; 72: 1001\u20131007.","DOI":"10.1161\/01.CIR.72.5.1001"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Betocchi S, Piscione F, Losi M A, Pace L, Boccalatte M, Perrone-Filardi P, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. The American Journal of Cardiology. 1996; 78: 451\u2013457.","DOI":"10.1016\/S0002-9149(96)00336-0"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Topriceanu CC, Field E, Boleti O, Cervi E, Kaski JP, Norrish G. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy. International Journal of Cardiology. 2023; 371: 523\u2013525.","DOI":"10.1016\/j.ijcard.2022.09.044"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Current Cardiology Reviews. 2016; 12: 52\u201365.","DOI":"10.2174\/1573403X1201160126125403"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Adler A, Fourey D, Weissler-Snir A, Hindieh W, Chan RH, Gollob MH, et al. Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients. Journal of the American Heart Association. 2017; 6: e005152.","DOI":"10.1161\/JAHA.116.005152"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Pollick C, Giacomini KM, Blaschke TF, Nelson WL, Turner-Tamiyasu K, Briskin V, et al. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation. 1982; 66: 447\u2013453.","DOI":"10.1161\/01.CIR.66.2.447"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Coppini R, Ferrantini C, Pioner JM, Santini L, Wang ZJ, Palandri C, et al. Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. JACC. Basic to Translational Science. 2019; 4: 795\u2013813.","DOI":"10.1016\/j.jacbts.2019.06.004"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Maurizi N, Chiriatti C, Fumagalli C, Targetti M, Passantino S, Antiochos P, et al. Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine. 2023; 12: 2725.","DOI":"10.3390\/jcm12072725"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science (New York, N.Y.). 2016; 351: 617\u2013621.","DOI":"10.1126\/science.aad3456"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2020; 396: 759\u2013769.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, et al. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2021; 78: 2518\u20132532.","DOI":"10.1016\/j.jacc.2021.09.1381"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. European Heart Journal. 2023; 44: 4622\u20134633.","DOI":"10.1093\/eurheartj\/ehad637"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Jaber WA, Nishimura RA, Ommen SR. Not all systolic velocities indicate obstruction in hypertrophic cardiomyopathy: a simultaneous Doppler catheterization study. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2007; 20: 1009.e5\u20131009.e7.","DOI":"10.1016\/j.echo.2007.01.015"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Geske JB, Cullen MW, Sorajja P, Ommen SR, Nishimura RA. Assessment of left ventricular outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis. JACC. Cardiovascular Interventions. 2012; 5: 675\u2013681.","DOI":"10.1016\/j.jcin.2012.01.026"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Elesber A, Nishimura RA, Rihal CS, Ommen SR, Schaff HV, Holmes DR, Jr. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. The American Journal of Cardiology. 2008; 101: 516\u2013520.","DOI":"10.1016\/j.amjcard.2007.09.111"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Cochran JM, Alam A, Guerrero-Miranda CY. Importance of right heart catheterization in advanced heart failure management. Reviews in Cardiovascular Medicine. 2022; 23: 12.","DOI":"10.31083\/j.rcm2301012"},{"key":"ref64","unstructured":"Present THE. Alcohol Septal Ablation for Obstructive. 2017; 70: 4\u201311."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Cardiology Clinics. 2011; 29: 269\u2013280.","DOI":"10.1016\/j.ccl.2011.03.003"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B\u00f6hm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016; 37: 1850\u20131858.","DOI":"10.1093\/eurheartj\/ehv727"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Berlin DA, Bakker J. Starling curves and central venous pressure. Critical Care (London, England). 2015; 19: 55.","DOI":"10.1186\/s13054-015-0776-1"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Moya A, Buytaert D, Penicka M, Bartunek J, Vanderheyden M. State-of-the-Art: Noninvasive Assessment of Left Ventricular Function Through Myocardial Work. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2023; 36: 1027\u20131042.","DOI":"10.1016\/j.echo.2023.07.002"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Gaasch WH, Meyer TE. Left ventricular response to mitral regurgitation: implications for management. Circulation. 2008; 118: 2298\u20132303.","DOI":"10.1161\/CIRCULATIONAHA.107.755942"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Hasenfuss G, Mulieri LA, Leavitt BJ, Allen PD, Haeberle JR, Alpert NR. Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circulation Research. 1992; 70: 1225\u20131232.","DOI":"10.1161\/01.RES.70.6.1225"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Rodriguez J, Schulz S, Voss A, Herrera S, Benito S, Giraldo BF. Baroreflex activity through the analysis of the cardio-respiratory variability influence over blood pressure in cardiomyopathy patients. Frontiers in Physiology. 2023; 14: 1184293.","DOI":"10.3389\/fphys.2023.1184293"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Norton JM. Toward consistent definitions for preload and afterload. Advances in Physiology Education. 2001; 25: 53\u201361.","DOI":"10.1152\/advances.2001.25.1.53"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Alter P, Rupp H, Rominger MB, Klose KJ, Maisch B. A new methodological approach to assess cardiac work by pressure-volume and stress-length relations in patients with aortic valve stenosis and dilated cardiomyopathy. Pflugers Archiv: European Journal of Physiology. 2008; 455: 627\u2013636.","DOI":"10.1007\/s00424-007-0323-2"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"St Goar FG, Masuyama T, Alderman EL, Popp RL. Left ventricular diastolic dysfunction in end-stage dilated cardiomyopathy: simultaneous Doppler echocardiography and hemodynamic evaluation. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 1991; 4: 349\u2013360.","DOI":"10.1016\/S0894-7317(14)80445-8"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives. International Journal of Cardiology. Heart & Vasculature. 2018; 18: 52\u201357.","DOI":"10.1016\/j.ijcha.2018.02.005"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989; 79: 483\u2013490.","DOI":"10.1161\/01.CIR.79.3.483"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Andersson B, Hamm C, Persson S, Wikstr\u00f6m G, Sinagra G, Hjalmarson A, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. Journal of the American College of Cardiology. 1994; 23: 1397\u20131404.","DOI":"10.1016\/0735-1097(94)90383-2"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Kim MH, Devlin WH, Das SK, Petrusha J, Montgomery D, Starling MR. Effects of beta-adrenergic blocking therapy on left ventricular diastolic relaxation properties in patients with dilated cardiomyopathy. Circulation. 1999; 100: 729\u2013735.","DOI":"10.1161\/01.CIR.100.7.729"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Tong X, Shen L, Zhou X, Wang Y, Chang S, Lu S. Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis. Drugs in R&D. 2023; 23: 197\u2013210.","DOI":"10.1007\/s40268-023-00435-5"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, et al. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. Circulation. 1993; 88: 481\u2013491.","DOI":"10.1161\/01.CIR.88.2.481"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, et al. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and \u03b2 blockers in patients with idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 2011; 107: 1065\u20131070.","DOI":"10.1016\/j.amjcard.2010.11.033"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Nikolaidis LA, Doverspike A, Huerbin R, Hentosz T, Shannon RP. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation. 2002; 105: 2785\u20132790.","DOI":"10.1161\/01.CIR.0000017433.90061.2E"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatric Cardiology. 1993; 14: 9\u201312.","DOI":"10.1007\/BF00794837"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Survey of Anesthesiology. 2000; 44: 182.","DOI":"10.1097\/00132586-200006000-00059"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. Journal of the American College of Cardiology. 2003; 41: 574\u2013581.","DOI":"10.1016\/S0735-1097(02)02855-3"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005; 112: 2940\u20132945.","DOI":"10.1161\/CIRCULATIONAHA.105.571653"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Januzzi JL, Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019; 322: 1085\u20131095.","DOI":"10.1001\/jama.2019.12821"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Kim HM, Kim KH, Park JS, Oh BH. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril\/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy. Medicina (Kaunas, Lithuania). 2021; 57: 416.","DOI":"10.3390\/medicina57050416"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"D\u00edez-Villanueva P, Vicent L, de la Cuerda F, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, de Juan-Bagud\u00e1 J, et al. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril\/Valsartan. Cardiology. 2020; 145: 275\u2013282.","DOI":"10.1159\/000505148"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annual Review of Physiology. 2021; 83: 503\u2013528.","DOI":"10.1146\/annurev-physiol-031620-095920"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Ji PJ, Zhang ZY, Yan Q, Cao HL, Zhao YJ, Yang B, et al. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. ESC Heart Failure. 2023; 10: 1314\u20131325.","DOI":"10.1002\/ehf2.14298"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Hong J, Huang L, Jin N, Zhao X, Hu J. Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: An observational study. Medicine. 2024; 103: e37579.","DOI":"10.1097\/MD.0000000000037579"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Psotka MA, Gottlieb SS, Francis GS, Allen LA, Teerlink JR, Adams KF, Jr, et al. Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019; 73: 2345\u20132353.","DOI":"10.1016\/j.jacc.2019.02.051"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (New York, N.Y.). 2011; 331: 1439\u20131443.","DOI":"10.1126\/science.1200113"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Solomon SD, Adams KF, Jr, Cleland JGF, et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet (London, England). 2016; 388: 2895\u20132903.","DOI":"10.1016\/S0140-6736(16)32049-9"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"R\u00f8nning L, Bakkehaug JP, R\u00f8dland L, Kildal AB, Myrmel T, How OJ. Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. Physiological Reports. 2018; 6: e13879.","DOI":"10.14814\/phy2.13879"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. The New England Journal of Medicine. 2021; 384: 105\u2013116.","DOI":"10.1056\/NEJMoa2025797"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Paulus WJ, Tsch\u00f6pe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal. 2007; 28: 2539\u20132550.","DOI":"10.1093\/eurheartj\/ehm037"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. Journal of the American College of Cardiology. 2009; 53: 905\u2013918.","DOI":"10.1016\/j.jacc.2008.12.007"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2016; 29: 277\u2013314.","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Nishimura RA, Redfield MM. Assessment of mean left atrial pressure from the left ventricular pressure tracing in patients with cardiomyopathies. The American Journal of Cardiology. 1996; 78: 107\u2013110.","DOI":"10.1016\/S0002-9149(96)00238-X"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Haskell RJ, French WJ. Accuracy of left atrial and pulmonary artery wedge pressure in pure mitral regurgitation in predicting left ventricular end-diastolic pressure. The American Journal of Cardiology. 1988; 61: 136\u2013141.","DOI":"10.1016\/0002-9149(88)91319-7"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Riccardi M, Pagnesi M, Sciatti E, Lombardi CM, Inciardi RM, Metra M, et al. Combined pre- and post-capillary pulmonary hypertension in left heart disease. Heart Failure Reviews. 2023; 28: 137\u2013148.","DOI":"10.1007\/s10741-022-10251-9"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Chaudhry A, Singer AJ, Chohan J, Russo V, Lee C. Interrater reliability of hemodynamic profiling of patients with heart failure in the ED. The American Journal of Emergency Medicine. 2008; 26: 196\u2013201.","DOI":"10.1016\/j.ajem.2007.04.029"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Costanzo-Nordin MR, O\u2019Connell JB, Engelmeier RS, Moran JF, Scanlon PJ. Dilated cardiomyopathy: functional status, hemodynamics, arrhythmias, and prognosis. Catheterization and Cardiovascular Diagnosis. 1985; 11: 445\u2013453.","DOI":"10.1002\/ccd.1810110502"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Pinamonti B, Zecchin M, Di Lenarda A, Gregori D, Sinagra G, Camerini F. Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy: an ominous prognostic sign. Journal of the American College of Cardiology. 1997; 29: 604\u2013612.","DOI":"10.1016\/S0735-1097(96)00539-6"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Stolfo D, Merlo M, Pinamonti B, Poli S, Gigli M, Barbati G, et al. Early improvement of functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy. The American Journal of Cardiology. 2015; 115: 1137\u20131143.","DOI":"10.1016\/j.amjcard.2015.01.549"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The Diagnosis and Evaluation of Dilated Cardiomyopathy. Journal of the American College of Cardiology. 2016; 67: 2996\u20133010.","DOI":"10.1016\/j.jacc.2016.03.590"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Ka\u017eukauskien\u0117 I, Bal\u010di\u016bnait\u0117 G, Baltr\u016bnien\u0117 V, \u010celutkien\u0117 J, Maneikien\u0117 VV, \u010cibiras S, et al. Left ventricular global longitudinal strain predicts elevated cardiac pressures and poor clinical outcomes in patients with non-ischemic dilated cardiomyopathy. Cardiovascular Ultrasound. 2021; 19: 21.","DOI":"10.1186\/s12947-021-00254-1"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: An Overview. International Journal of Molecular Sciences. 2021; 22: 7722.","DOI":"10.3390\/ijms22147722"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, et al. Restrictive cardiomyopathy: definition and diagnosis. European Heart Journal. 2022; 43: 4679\u20134693.","DOI":"10.1093\/eurheartj\/ehac543"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Mogensen J, van Tintelen JP, Fokstuen S, Elliott P, van Langen IM, Meder B, et al. The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. European Heart Journal. 2015; 36: 1367\u20131370.","DOI":"10.1093\/eurheartj\/ehv122"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Kaski JP, Syrris P, Burch M, Tom\u00e9-Esteban MT, Fenton M, Christiansen M, et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart (British Cardiac Society). 2008; 94: 1478\u20131484.","DOI":"10.1136\/hrt.2007.134684"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Goldstein JA, Kern MJ. Hemodynamics of constrictive pericarditis and restrictive cardiomyopathy. Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions. 2020; 95: 1240\u20131248.","DOI":"10.1002\/ccd.28692"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009; 120: 1203\u20131212.","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Sanchorawala V. Systemic Light Chain Amyloidosis. The New England Journal of Medicine. 2024; 390: 2295\u20132307.","DOI":"10.1056\/NEJMra2304088"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine. 2024; 390: 132\u2013142.","DOI":"10.1056\/NEJMoa2305434"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. The New England Journal of Medicine. 2018; 379: 11\u201321.","DOI":"10.1056\/NEJMoa1716153"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. The New England Journal of Medicine. 2023; 389: 1553\u20131565.","DOI":"10.1056\/NEJMoa2300757"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Coelho T, Marques W, Jr, Dasgupta NR, Chao CC, Parman Y, Fran\u00e7a MC, Jr, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023; 330: 1448\u20131458.","DOI":"10.1001\/jama.2023.18688"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Brannagan TH, Coelho T, Wang AK, Polydefkis MJ, Dyck PJ, Berk JL, et al. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. Journal of Neurology. 2022; 269: 6416\u20136427.","DOI":"10.1007\/s00415-022-11276-8"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. The New England Journal of Medicine. 2021; 385: 493\u2013502.","DOI":"10.1056\/NEJMoa2107454"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2021; 77: 922\u2013936.","DOI":"10.1016\/j.jacc.2020.12.024"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, St\u00f6rk S, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009; 119: 524\u2013529.","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone Therapy in Fabry Disease. International Journal of Molecular Sciences. 2022; 23: 1887.","DOI":"10.3390\/ijms23031887"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Vardarli I, Weber M, Rischpler C, F\u00fchrer D, Herrmann K, Weidemann F. Fabry Cardiomyopathy: Current Treatment and Future Options. Journal of Clinical Medicine. 2021; 10: 3026.","DOI":"10.3390\/jcm10143026"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Domm JM, Wootton SK, Medin JA, West ML. Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. Molecular Genetics and Metabolism. 2021; 134: 117\u2013131.","DOI":"10.1016\/j.ymgme.2021.07.006"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Kang Y, Qu N, Zhang Z, Zhang Q, Chen X, Fu M. Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis. International Journal of Cardiology. 2024; 402: 131813.","DOI":"10.1016\/j.ijcard.2024.131813"},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research. 2017; 121: 819\u2013837.","DOI":"10.1161\/CIRCRESAHA.117.310982"},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Bukhari S, Oliveros E, Parekh H, Farmakis D. Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis. Current Problems in Cardiology. 2023; 48: 101571.","DOI":"10.1016\/j.cpcardiol.2022.101571"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023; 329: 827\u2013838.","DOI":"10.1001\/jama.2023.2020"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020; 75: 1178\u20131195.","DOI":"10.1016\/j.jacc.2019.12.059"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021; 144: 1284\u20131294.","DOI":"10.1161\/CIRCULATIONAHA.121.056824"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Peikert A, Martinez FA, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation. Heart Failure. 2022; 15: e010080.","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Verma A, Patel AB, Waikar SS. SGLT2 Inhibitor: Not a Traditional Diuretic for Heart Failure. Cell Metabolism. 2020; 32: 13\u201314.","DOI":"10.1016\/j.cmet.2020.06.014"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC. Basic to Translational Science. 2020; 5: 632\u2013644.","DOI":"10.1016\/j.jacbts.2020.02.004"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Nakatsukasa T, Ishizu T, Ouchi M, Murakoshi N, Sato K, Yamamoto M, et al. Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure. Circulation Journal: Official Journal of the Japanese Circulation Society. 2022; 86: 2029\u20132039.","DOI":"10.1253\/circj.CJ-22-0105"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Garcia MJ. Constrictive Pericarditis Versus Restrictive Cardiomyopathy? Journal of the American College of Cardiology. 2016; 67: 2061\u20132076.","DOI":"10.1016\/j.jacc.2016.01.076"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Geske JB, Anavekar NS, Nishimura RA, Oh JK, Gersh BJ. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. Journal of the American College of Cardiology. 2016; 68: 2329\u20132347.","DOI":"10.1016\/j.jacc.2016.08.050"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. Journal of the American College of Cardiology. 2018; 71: 1130\u20131148.","DOI":"10.1016\/j.jacc.2018.01.016"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/12\/10.31083\/j.rcm2512455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:57:30Z","timestamp":1735556250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/12\/10.31083\/j.rcm2512455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":142,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"alternative-id":["S1530-6550(24)01582-5"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2512455","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"article-number":"455"}}